

# GenomeQuest

## WHY GQ-PAT PLATINUM?

Because no search can be called comprehensive without looking at this large and growing database, built to double search efficiency by putting more information at the searcher's fingertips.

### GENOMEQUEST'S PLATINUM SEQUENCE DATABASE

## EXPANDED CONTENT DUE TO MANUAL PARSING

GenomeQuest has diversified its sources of content, adding both public and commercial sources. We have also made significant additions to staff to enable manual parsing of sequences, SEQ IDs, and claim locations in text, tables, and figures.

The entire backfile of non-ST.25 authorities such as China, Russia, India, and Brazil, plus non-ST.25 documents from major authorities such as US, EP, WO, JP, and KR will be complete in early 2015, yielding over 600,000 patent documents.

We will then manually parse sequences, SEQ IDs, and claim locations in figures and tables from our GQ-Pat Gold database.

Gold+ has **18%** more documents than Gold. Platinum has **30%** more documents than Gold and includes all of Gold+. Both include all of the features described here.

## UNIQUE FAMILY SEQUENCE

Often, the same sequence can be found more than once in a patent family. The Unique Family Sequence field is an ID that is the same for all identical sequences within a family. Using it, one can merge all identical sequences within GQ-Pat families.

### Uses and Benefits

- Group by UFS can advantageously **replace group by family**, giving **finer grain resolution of unique hits within a family**.
- Break down a sequence's status across authorities** by summarizing all PNs, sequence location, legal status, and relevant dates for each UFS.
- Decrease computation time** by searching only against the UFS rather than every copy of the sequence.\*

\* coming soon

### Total Documents in GQ-Pat Platinum

|              |                | 2012                  | 2013                  | end of 2014           |
|--------------|----------------|-----------------------|-----------------------|-----------------------|
| US           | Gold+          | 187,825<br>13%        | 212,618<br>13%        | 238,642<br>12%        |
| EPO          | Gold+          | 38,330<br>10%         | 43,252<br>13%         | 50,316<br>16%         |
| WIPO         | Gold+          | 81,456<br>7%          | 89,585<br>10%         | 111,212<br>24%        |
| Canada       | Gold+          | 8                     | 1,447<br>17,988%      | 41,724<br>2,783%      |
| Japan        | Gold+          | 55,487<br>8%          | 63,778<br>15%         | 69,146<br>8%          |
| Korea        | Gold+          | 7,428<br>0%           | 32,545<br>338%        | 36,748<br>13%         |
| China        | Platinum       | 11,310<br>40%         | 26,233<br>132%        | 62,591<br>139%        |
| India        | Platinum       | 685                   | 1,761<br>157%         | 2,262<br>28%          |
| Others       | Blended        | 1,306<br>21%          | 3,351<br>157%         | 4,780<br>43%          |
| <b>Total</b> | <b>Blended</b> | <b>383,835</b><br>11% | <b>474,570</b><br>24% | <b>617,421</b><br>30% |

## US PAIR

GQ-Pat now includes legal status information from US PAIR (Patent Application Information Retrieval). This content is updated once a month.

| Document ID   | Title  | Legal Status  | Effective Date  | Expiration Date         |
|---------------|--|---|---|-------------------------|
| US20020198371 | 1-1 of 3 [ View all 3 Results ]  |   |   |                         |
| US20020198371 | SNP CONSORTIUM [US]  | Identification and mapping of single nucleotide polymorphisms in the human genome | Abandoned Failure to Respond to an Office Action [USPAIR] | 30-Oct-2003 09-Aug-1999 |
| US20140094381 | 1-1 of 1   |   |   |                         |
| US20140094381 | MEDICAL PROGNOSIS INSTITUTE A/S HORSHOLM, DENMARK - BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE BATON ROUGE, LA | Predictive Biomarkers for Response to Exercise                                    | Docketed New Case Ready for Examination [USPAIR]          | 03-Apr-2014 04-Sep-2009 |

# EXTENDED LEGAL STATUS AND NATIONAL PHASE LEGAL STATUS

When doing searches for patents using GenomeQuest's premier IP product you will be able to view legal statuses beyond *Granted* and *Application*. Utilizing this legal status provides you with a more in depth view of the patent or application status, allowing you to make a more informed decision when it comes to freedom to operate and marketability of your sequence patent.

GenomeQuest also allows you to view the legal status by nation, or the so-called Legal Status National Phase. For example, perhaps the patent you are looking at simply states *Revoked*, but you do not know where that status of is applicable. National Phase will list legal status specifically by country.

## Extended Legal Status Values

|                |   |
|----------------|---|
| <b>Pending</b> | Patent applications in a pre-grant or a pre-rejection stage   |
| <b>Granted</b> | Granted patents in a post-decision stage  |
| <b>Lapsed</b>  | Office statuses such as lapsed, abandoned, withdrawn, or surrendered. Patent not in force.                    |
| <b>Expired</b> | Granted patents that have expired due to normal life of the patent cycle.                                     |
| <b>Revoked</b> | Patents or published applications not in force before the end of the normal term because of an office action. |

## National Phase Legal Status

AU=GRANTED, CA=PENDING, CN=PENDING, DE=LAPSED, EP=PENDING, IN=PENDING, JP=PENDING, KR=PENDING, MX=PENDING, MY=PENDING, RU=PENDING, US=PENDING, WO=LAPSED

# NORMALIZED ASSIGNEES AND PARENT COMPANIES

When searching patents the patent assignee field can be one of the most important. Many times confusion can be caused by multiple patent assignee names due to several forms of same assignee within publications, name changes, or other data abnormalities.

GQ-Pat Platinum provides two fields to address this challenge. The **Normalized Patent Assignee** field takes all the various versions of a single, specific patent publisher and displays a single unique assignee name, enabling filtering, grouping, and sorting on the field. The **Normalized Parent** field determines the parent company, if any, relating to the patent assignee. For instance, a MedImmune patent would have the word "AstraZeneca" as its Normalized Parent, since they acquired MedImmune in 2007. Roughly 40% of the documents in GQ-Pat have such parents.



## How do I get access to GQ-Pat Platinum?

Sequences from these BRIC applications and patents, as well as the Extended Legal Status, the Legal Status National Phase, Unique Family Sequence, Normalized Patent Assignee, and Normalized Parent are available by upgrading to a Platinum seat for an additional charge.

For customers not interested in patents from emerging markets, GenomeQuest also offers a Gold+ seat, with U.S., WIPO, EPO, and Japanese non ST.25 docs, which also includes the Extended Legal Status, National Phase, Unique Family Sequence, and the normalizations on patent assignee and parent.

**Call +1 508 616 0100 or email [sales@genomequest.com](mailto:sales@genomequest.com)**

**GenomeQuest, Inc  
4325 Alexander Drive Suite 100  
Alpharetta, GA 30022**